Drugs / Dextrose
last change 6 days ago re-read 9 days ago

Dextrose

targets TRPV1 via inhibition

Developed for
osteoarthritis, knee · carpal tunnel syndrome · frozen shoulder · chronic pain syndrome · temporomandibular joint disorder · epicondylitis · hypermobility syndrome · myofascial pain syndrome
+30 more · osteoarthritis, hand · rotator cuff syndrome · arthropathy · chronic kidney disease · chronic renal failure syndrome · Ehlers-Danlos syndrome, hypermobility type · end stage renal failure · gastroschisis · hypermobility spectrum disorder · hypoglycemia · intermediate coronary syndrome · interstitial cystitis · lumbar disk degenerative disorder · lumbar spinal stenosis · meralgia paresthetica · musculoskeletal system disorder · myocardial infarction · pes anserinus tendinitis or bursitis · plantar fasciitis · post-traumatic stress disorder · pulmonary immaturity · sciatica · subacute bursitis · symptomatic heart failure · tendinosis · type 2 diabetes mellitus · acute tubulointerstitial nephritis · enthesopathy · radial nerve lesion · ulnar neuropathy
Investigated by
Tri-Service General Hospital (TSGH) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Mayo Clinic · University of Alexandria · Alexandria University · Christine M. Kleinert Institute for Hand and Microsurgery
+73 more · Hadassah Medical Organization · Hasanuddin University · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Taipei Medical University · University of Malaya · Yale University · Academic Pediatric Association · Ahi Evran University Education and Research Hospital · Ain Shams University · Aksaray University Training and Research Hospital · American Academy of Pediatrics · American Association of Orthopaedic Medicine · Assiut University · Azienda Ospedaliera di Padova · Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital · Bangladesh Medical University · Baxter Healthcare Corporation · British Columbia Cancer Agency · Bumi Herman · Cairo University · Cecilia Calvo · Chang Gung Memorial Hospital · Children's Hospital of Philadelphia · Dinara Zhumanbayeva · Dr Cipto Mangunkusumo General Hospital · Dr. Dean Reeves Clinic · First Affiliated Hospital, Sun Yat-Sen University · Fisiatria y Traumatología · Helena Hildenwall · Hospital Universitario La Paz · Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Kamuzu University of Health Sciences · Karadeniz Technical University · Kleinert, Kutz and Associates · Makerere University · Manhattan Pain Medicine, PLLC · McGill University Health Centre/Research Institute of the McGill University Health Centre · Mexican Social Security Institute · Ministry of Health, Malaysia · Ministry of Science and Technology, Taiwan · National Center for Complementary and Integrative Health (NCCIH) · National Cheng-Kung University Hospital · National Defense Medical Center, Taiwan · National Health Research Institutes, Taiwan · National Heart, Lung, and Blood Institute (NHLBI) · National Taiwan University Hospital · National Yang Ming Chiao Tung University Hospital · Nourhan M.Aly · Ondokuz Mayıs University · Ordu University · Ospedali Riuniti Ancona · Penang Hospital, Malaysia · Reuth Rehabilitation Hospital · Rizki Darmawan · Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur, Indonesia · Sequana Medical N.V. · Sheikh Zayed Medical College · Shin Kong Wu Ho-Su Memorial Hospital · Suez Canal University · Tanta University · The Cleveland Clinic · The Seekers Centre · Thomas Jefferson University · Tufts Medical Center · Tulane University · Universidad Nacional de Rosario · University Medical Centre Ljubljana · University of Arkansas · University of Kansas Medical Center · University of Pittsburgh · University of Saskatchewan · University of Targu Mures, Romania · Yonsei University

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) DEXTROSE 70% IN PLASTIC CONTAINER — 2000-12-07 fda.gov ↗
Label expansion US (FDA) DEXTROSE 50% — 1998-11-23 fda.gov ↗
Approved US (FDA) ALCOHOL 5% AND DEXTROSE 5% — 1946-01-17 fda.gov ↗

Trials 76 · started per year

today
US approved 1946
1
2
1
2
2
4
1
3
5
6
7
3
7
6
9
6
6
4
1
194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT04832009 May 2022 → Aug 2026 overdue hypertensive disorder University of Kansas Medical Center Recruiting No outcome recorded
Phase 0 NCT03801226 Dec 2018 → May 2019 symptomatic heart failure Yale University Completed No outcome recorded
Phase 14 trials
Phase 1 NCT05780086 Feb → Aug 2023 chronic kidney disease Mexican Social Security Institute Unknown No outcome recorded
Phase 1 NCT05185999 Oct 2022 → Oct 2023 chronic renal failure syndrome London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Completed No outcome recorded
Phase 1 NCT04640662 Feb 2020 → Jun 2021 tendinosis University of Malaya Completed No outcome recorded
Phase 1 NCT03205553 Feb → May 2018 gastroschisis University of Arkansas Terminated No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07688096 Jan → Dec 2027 expected Ehlers-Danlos syndrome, hypermobility type, chronic pain syndrome, hypermobility spectrum disorder, hypermobility syndrome Manhattan Pain Medicine, PLLC Not yet recruiting No outcome recorded
Phase 1/2 NCT06829030 Jul 2024 → Feb 2025 overdue — Aksaray University Training and Research Hospital Enrolling by invitation No outcome recorded
Phase 27 trials · 1 met primary
Phase 2 NCT07548047 Jun 2026 → Jun 2028 expected — Thomas Jefferson University Not yet recruiting No outcome recorded
Phase 2 NCT06293885 Mar 2024 → Apr 2025 — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Unknown No outcome recorded
Phase 2 NCT05160532 Apr 2022 → May 2025 osteoarthritis, knee Mayo Clinic Completed No outcome recorded
Phase 2 NCT04557878 Oct 2020 → Apr 2021 temporomandibular joint disorder Nourhan M.Aly Completed No outcome recorded
Phase 2 NCT02796729 Oct 2016 → Dec 2018 metastatic malignant neoplasm in the brain British Columbia Cancer Agency Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT01897259 Mar 2012 → Jun 2019 epicondylitis Christine M. Kleinert Institute for Hand and Microsurgery Unknown No outcome recorded
Phase 2 NCT01285713 Sep 2010 → Aug 2011 — Children's Hospital of Philadelphia Completed Met primary
Phase 2/35 trials
Phase 2/3 NCT06859034 Mar → Sep 2025 overdue temporomandibular joint disorder Cairo University Not yet recruiting No outcome recorded
Phase 2/3 NCT05548738 Apr 2022 → Nov 2023 chronic pain syndrome Alexandria University Completed No outcome recorded
Phase 2/3 NCT04802785 Jun → Jul 2021 — Dinara Zhumanbayeva Unknown No outcome recorded
Phase 2/3 NCT01210183 Jul 2010 → Dec 2013 osteoarthritis, knee Universidad Nacional de Rosario Completed No outcome recorded
Phase 2/3 NCT00674622 Sep 2007 → Oct 2010 epicondylitis University of Pittsburgh Completed No outcome recorded
Phase 35 trials · 1 missed
Phase 3 NCT05279937 Oct 2026 Ehlers-Danlos syndrome Tulane University Withdrawn No outcome recorded Stop: Business
Phase 3 NCT07102225 May 2025 → Sep 2026 overdue osteoarthritis, knee Bangladesh Medical University Active not recruiting No outcome recorded
Phase 3 NCT06847594 Feb → Sep 2024 — Ain Shams University Completed No outcome recorded
Phase 3 NCT04791202 Apr 2021 → Mar 2022 — Christine M. Kleinert Institute for Hand and Microsurgery Unknown No outcome recorded
Phase 3 NCT00091507 Nov 2006 → Aug 2011 congestive heart failure, intermediate coronary syndrome, myocardial infarction Tufts Medical Center Completed Missed primary
Phase 417 trials · 1 met primary
Phase 4 NCT07382596 May 2026 → Mar 2030 expected post-traumatic stress disorder Dr. Dean Reeves Clinic Recruiting No outcome recorded
Phase 4 NCT06726980 Jan 2025 → Jan 2026 overdue — Assiut University Not yet recruiting No outcome recorded
Phase 4 NCT06349824 Oct 2023 → Mar 2024 carpal tunnel syndrome Sheikh Zayed Medical College Completed No outcome recorded
Phase 4 NCT05977985 Aug 2023 → Jul 2024 frozen shoulder University of Malaya Unknown No outcome recorded
Phase 4 NCT05918146 Jun 2023 → Jun 2024 subacute bursitis Taipei Medical University Unknown No outcome recorded
Phase 4 NCT05264727 May 2023 → Dec 2025 overdue obesity disorder, type 2 diabetes mellitus Mayo Clinic Active not recruiting No outcome recorded
Phase 4 NCT05721404 May 2023 → Apr 2027 expected — First Affiliated Hospital, Sun Yat-Sen University Recruiting No outcome recorded
Phase 4 NCT05131269 Dec 2021 → May 2022 frozen shoulder Bumi Herman Completed No outcome recorded
Phase 4 NCT03693287 Jul 2021 → Aug 2023 pulmonary immaturity Ospedali Riuniti Ancona Unknown No outcome recorded
Phase 4 NCT04062838 Aug 2020 → Dec 2021 rotator cuff syndrome Hadassah Medical Organization Withdrawn No outcome recorded Stop: Business
Phase not applicable34 trials · 3 met primary · 3 missed
— NCT07498998 Jul → Aug 2026 overdue carpal tunnel syndrome Tanta University Not yet recruiting No outcome recorded
— NCT06872645 Oct 2025 → Jun 2028 expected — Yale University Recruiting No outcome recorded
— NCT07559058 Oct 2025 → Jan 2026 frozen shoulder, rotator cuff syndrome Rizki Darmawan Completed No outcome recorded
— NCT07479693 Jan → Aug 2025 hydrarthrosis, temporomandibular joint disorder Ondokuz Mayıs University Completed No outcome recorded
— NCT06617065 Sep 2024 → Jan 2025 overdue chronic pain syndrome The Seekers Centre Active not recruiting No outcome recorded
— NCT06165926 Jan → Dec 2024 frozen shoulder Tri-Service General Hospital (TSGH) Unknown No outcome recorded
— NCT06165939 Jan → Dec 2024 frozen shoulder Tri-Service General Hospital (TSGH) Unknown No outcome recorded
— NCT05984121 Aug → Dec 2023 plantar fasciitis Ahi Evran University Education and Research Hospital Completed No outcome recorded
— NCT05966948 May → Sep 2023 obesity disorder, osteoarthritis, knee Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur, Indonesia Completed No outcome recorded
— NCT06301958 Jan 2023 → Aug 2024 arthropathy Chang Gung Memorial Hospital Unknown No outcome recorded
Comparator or background therapy64 trials
Phase 0 NCT07296653 Comparator Dec 2025 → Dec 2026 expected — National and Kapodistrian University of Athens Recruiting No outcome recorded
Phase 0 NCT04133922 Comparator Oct 2019 → Oct 2023 type 1 diabetes mellitus University of Virginia Withdrawn No outcome recorded
Phase 0 NCT03520569 Comparator Feb 2019 → Apr 2021 arterial disorder University of Virginia Completed No outcome recorded
Phase 0 NCT02982551 Background Jan 2016 → Dec 2017 — University of Pittsburgh Withdrawn No outcome recorded
Phase 1 NCT07224334 Background Dec 2025 → Dec 2027 expected diabetes mellitus David D'Alessio, M.D. Recruiting No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 143 sources stand behind the page.

FieldValueCited text
Known as Dextrose “Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the...” NCT04557943 ↗
137

“bolus of 1-3 IU/kg regular insulin together with 0.5-1 gm/kg dextrose followed by an intravenous infusion of 0.2 to 1 IU/kg/hr of regular insulin and a dextrose infusion will...” NCT07451561 ↗

“1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.” NCT05984121 ↗

“Prolotherapy group Patients in the prolotherapy group will receive a single 2 mL injection of 16.5% dextrose solution administered under ultrasound guidance.” NCT04640662 ↗

“Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.” NCT00753142 ↗

“Intravenous glucose will be "dextrose 50%", amino acids (AA) will be "Primene®" and lipids (FAT) will be "Clinoleic®".” NCT03693287 ↗

“Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.” NCT01897259 ↗

“Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique.” NCT04395417 ↗

“prior controlled study reported short-term pain relief after caudal epidural injection of 5% dextrose (D5W)” PMID 29883193 ↗ Jun 2018

“Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast” NCT00749827 ↗

“an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered.” NCT02746432 ↗

Show 127 more sources

Known as 5% Dextrose “500 ml of 5% Dextrose administered to a peripheral vein.” NCT04150978 ↗
Known as 5% dextrose injection “Drug: 5% dextrose injection” NCT07241559 ↗
Known as D-glucose “Prolo Group: All participants will receive 15% dextrose (D-glucose) with 1% lidocaine.” NCT07296653 ↗
1

“dextrose, also known as d-glucose” NCT04821882 ↗

Known as D10W “dextrose 10% (D10W ®) infusion” NCT00774098 ↗
Known as D5W “perineural injection of peripheral nerves, plexi, or sympathetic ganglia with dextrose 5% in water (D5W), has performed well empirically in the treatment of post-traumatic...” NCT07382596 ↗
4

“The effect of injecting 1 mL each of normal saline and 5% dextrose in water (NS and D5W) on muscle twitch was investigated at all 20 needle insertion sites.” PMID 15138901 ↗ May 2004

“Perineural injection with 5% dextrose (D5W).” NCT07498998 ↗

“Drug: Dextrose 5% (D5W)” NCT02331069 ↗

“5% dextrose (D5W)” PMID 31368191 ↗ Aug 2019

Known as Dextrose 20 % in Water “Drug: Dextrose 20 % in Water” NCT04133922 ↗
Known as Dianeal PD-2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04887480 ↗
Known as Glucose “Using Dextrose (Glucose) Gel to Reverse Neonatal Hypoglycemia.” PMID 28764827 ↗ Jul 2017
Known as perineural dextrose injection “perineural dextrose injection” NCT07002892 ↗
Known as Peritoneal Dialysis Solution/Dextrose ClinicalTrials.gov intervention name — accepted as the source's own label NCT03205553 ↗
Action Inhibit “5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.” NCT02809261 ↗
Route Intravenous “Intravenous solution” NCT00091507 ↗
Target TRPV1 “Perineural prolotherapy (glucose concentration DW 5%) seems to exert therapeutic effects by inhibiting the activation of the TRPV1 pain receptor located at the terminals of...” NCT07245121 ↗